Key result
HELP apheresis improves clinical status in two patients with acute cardiovascular syndromes ineligible for conventional therapy.
Why the study?
Does HELP apheresis improve clinical outcomes in patients with acute cardiovascular syndromes who are ineligible for conventional reperfusion therapy?
Case Report (n=2)
Does HELP apheresis improve clinical outcomes in patients with acute cardiovascular syndromes who are ineligible for conventional reperfusion therapy?
HELP apheresis may offer a novel salvage approach for patients with acute cardiovascular syndromes who are ineligible for standard reperfusion therapies.
May offer salvage option in reperfusion-ineligible acute syndromes; leaves open efficacy, requiring prospective trials.
We report the first experiences with HELP apheresis as an emergency treatment for acute cardiovascular syndromes; two patients who were not eligible for lysis therapy and catheter intervention were treated with HELP apheresis instead. Both patients had a most severe, generalized atherosclerosis and reached the hospital too late for conventional measures. In both cases, the use of the apheresis dramatically improved the clinical situation to such an extent that the possibilities of this apheresis system urge further investigation.
No takes yet. Share an insight, caveat, or question.
Jaeger et al. (2002) conducted a case report in Acute cardiovascular syndromes (n=2). HELP apheresis (Heparin-Mediated Low-Density Lipoprotein/Fibrinogen Precipitation) was evaluated on Clinical situation improvement. HELP apheresis dramatically improved the clinical situation in two patients with acute cardiovascular syndromes who were ineligible for conventional lysis therapy and catheter intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: